Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Ozon plans to complete settlements with bondholders for $750 million in April

3/30/23 OZON

I.A. Likhachev Plant reported for 2022 according to RAS

3/29/23 ZILL

Nornickel will expand production in Finland

3/29/23 GMKN

Most popular show in Runet will be released exclusively on VK Video

3/29/23 VKCO

Bluebird bio reported for 2022

3/29/23 BLUE

Krasny Oktyabr reported for 2022 according to RAS

3/29/23 KROT

Bashinformsvyaz reported for 2022 according to RAS

3/29/23 BISVP

Genetico will hold an IPO on the Moscow Exchange

3/29/23 ABIO

Rosneft and Indian Oil have agreed to increase oil supplies to India

3/29/23 ROSN

Kamaz plans to open a production and service center in Kyrgyzstan

3/29/23 KMAZ